UK markets closed

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.4350-0.0086 (-1.94%)
As of 02:25PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 24.28M
Enterprise value -38.45M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.42
Price/book (mrq)0.81
Enterprise value/revenue 4.83
Enterprise value/EBITDA -2.32

Trading information

Stock price history

Beta (5Y monthly) 0.79
52-week change 3-86.12%
S&P500 52-week change 323.23%
52-week high 34.4500
52-week low 30.4101
50-day moving average 30.7224
200-day moving average 31.0064

Share statistics

Avg vol (3-month) 3395.69k
Avg vol (10-day) 3627.13k
Shares outstanding 554.68M
Implied shares outstanding 654.68M
Float 846.61M
% held by insiders 115.25%
% held by institutions 143.73%
Shares short (15 May 2024) 42.44M
Short ratio (15 May 2024) 48.38
Short % of float (15 May 2024) 45.20%
Short % of shares outstanding (15 May 2024) 44.47%
Shares short (prior month 15 Apr 2024) 42.61M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,277.05%

Management effectiveness

Return on assets (ttm)-62.20%
Return on equity (ttm)-147.29%

Income statement

Revenue (ttm)16.94M
Revenue per share (ttm)0.31
Quarterly revenue growth (yoy)-65.40%
Gross profit (ttm)N/A
EBITDA -120.87M
Net income avi to common (ttm)-122.54M
Diluted EPS (ttm)-2.2600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)69.77M
Total cash per share (mrq)1.28
Total debt (mrq)7.04M
Total debt/equity (mrq)23.64%
Current ratio (mrq)5.38
Book value per share (mrq)0.55

Cash flow statement

Operating cash flow (ttm)-87.91M
Levered free cash flow (ttm)-49.98M